WALTHAM,
Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that on January 1,
2025 the Company granted inducement awards to purchase up to
123,100 shares of common stock to five new employees under the
Company's 2023 Inducement Plan. The stock options will vest over
four years, with 25% of the underlying shares vesting on the
one-year anniversary of the vesting commencement date and 1/48th of
the underlying shares vesting monthly thereafter over 36 months,
subject to the employee's continued service relationship with
Syndax through the applicable vesting dates.
About Syndax
Syndax Pharmaceuticals is a
commercial-stage biopharmaceutical company developing an innovative
pipeline of cancer therapies. Highlights of the Company's pipeline
include Revuforj® (revumenib), an FDA-approved
menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor. Fueled by our commitment to reimagining cancer
care, Syndax is working to unlock the full potential of its
pipeline and is conducting several clinical trials across the
continuum of treatment. For more information, please
visit www.syndax.com or follow the Company on X
and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original
content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302341648.html
SOURCE Syndax Pharmaceuticals, Inc.